Immunovant COO Melanie Gloria sells shares worth $71,846

On October 7, 2026, Immunovant, Inc.'s Chief Operating Officer, Melanie Gloria, sold 2,241 shares of the company's common stock, amounting to a total value of $71,846. The shares were sold at prices between $31.58 and $32.30, with an average price of $32.06 per share. The stock, currently trading at $30.47, saw a decline of about 9% over the previous week. However, Immunovant's stock has shown a remarkable 74% return over the past year.

This transaction was a 'sell to cover' sale, which Ms. Gloria was obligated to execute to fulfill tax withholding requirements associated with the vesting of 4,761 restricted stock units (RSUs). These RSUs were granted to her on April 1, 2025, and were scheduled to vest on October 1, 2026. This sale was not a discretionary decision by Ms. Gloria, but rather a necessary action mandated by Immunovant, Inc. as a result of the RSU vesting.

Following the sale, Ms. Gloria now directly owns 217,060 shares of Immunovant common stock. Recent analysis from InvestingPro suggests that the stock may be overvalued at its current price. For those interested in a more detailed analysis, the Pro Research Report for Immunovant and over 1,400 other US stocks can be accessed through InvestingPro.

Meanwhile, Immunovant's development of its IMVT-1402 drug candidate for cutaneous lupus erythematosus was halted after it failed to meet the primary endpoint in a clinical trial involving 57 patients. The trial did not achieve statistical significance, leading to the discontinuation of the drug's development for this indication.

Despite this setback, H.C. Wainwright has maintained a 'Buy' rating for Immunovant, setting a price target of $41.00. Additionally, Cantor Fitzgerald has reiterated an 'Overweight' rating on Immunovant following the company's first-quarter earnings report, updating its financial model based on the company’s operating expenses.

Roivant Sciences, a company associated with Immunovant, reported a wider-than-expected first-quarter loss with earnings per share of -$0.75, which missed analysts' forecast of -$0.60. The loss was attributed to increased spending on research and development and commercial preparation. However, the company did not provide detailed near-term revenue information to investors. These developments underscore the ongoing challenges and strategic decisions faced by the company.